AlphAIAlphAI — Financial news for AI agents
news.alphastreet.comOCT 201 min read$LQDA

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

Original reporting
news.alphastreet.com
Published Oct 20, 2026, 3:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy — source image
Source · news.alphastreet.com
Decision brief

The 30-second read

$LQDABullishMed
01

Why it matters

Analyst consensus upgrades drive a 6.3% price jump, suggesting momentum may continue.

02

Market read

The upgrade-driven rally highlights fresh buying interest in LQDA.

03

What to watch

Potential regulatory or clinical trial setbacks could temper upside.

Relevance 7/10Novelty 7/10Timing: intraday today

Background

Liquidia Corp (LQDA) is a specialty drug manufacturer with a $3.2B market cap.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

Analyst upgrades and higher price targets lifted LQDA 6.3% intraday, indicating fresh bullish sentiment.

Expected impact

likely upward pressure as the market prices in higher targets

Evidence & confidence

Multiple firms raised targets today, with the highest at $70, supporting further price gains.

Market effects

Sector

Boosts sentiment for the specialty drug sector as analysts show confidence in pipeline execution.

Regional

Positive for US biotech stocks, may lift related peers.

Global

Limited to US-listed biotech investors.

Counterpoint

What could challenge this read

Price may be overbought after a sharp move; wait for a pullback.

Key entities

  • company
    Liquidia Corporation

    Specialty drug manufacturer

Read at source← All news

Related articles

OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min